OP23 The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12Axel Dignaß, Jessica R. Allegretti, David T. Rubin et al.|Journal of Crohn s and Colitis|2022Cited by 17
OP37 Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFIWilliam J. Sandborn, Colleen Marano, B E Sands et al.|Journal of Crohn s and Colitis|2019Cited by 15
DOP54 Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trialSilvio Danese, Gert Van Assche, H Zhang et al.|Journal of Crohn s and Colitis|2019Cited by 8
Efficacy and Safety of Ustekinumab as Maintenance Therapy in Ulcerative Colitis: Week 44 Results from UNIFIWJ Sandborn, Colleen Marano, BE Sands et al.|Zeitschrift für Gastroenterologie|2019Cited by 7
P312 Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate–severe ulcerative colitis: UNIFIB E Sands, William J. Sandborn, Laurent Peyrin‐Biroulet et al.|Journal of Crohn s and Colitis|2019Cited by 5